Biopharma | May 05, 2026
Zydus Lifesciences subsidiary faces Rs 9 million GST demand notice
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
The company says the product will now be distributed exclusively through Anovo Specialty Pharmacy
New policy aims to standardise screening, diagnosis and lifelong care for children with diabetes across India’s public health system
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Week-long Fire Safety Week 2026 campaign focuses on strengthening fire prevention, preparedness, audits, and emergency response across hospitals and healthcare facilities
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
Subscribe To Our Newsletter & Stay Updated
